SCHEMBL3075340

SCHEMBL3075340

c1ccc2[nH]c3ncnc-3cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.44
PDGFRB P09619 1/20 0.42
FGFR1 P11362 1/20 0.42
KDR P35968 1/20 0.42
GSK3B P49841 1/20 0.42
ESR1 P03372 2/20 0.41
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
KDM4E B2RXH2 5/20 0.41
PKM P14618 4/20 0.41
HSD17B10 Q99714 3/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
ABCB11 O95342 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.40
LOXL2 Q9Y4K0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22134394 0.74 DAO (0.47) RAB9ANPC1SMN1; SMN2KDM4EPKM
SCHEMBL142585 0.74 DAO (0.47) KDRMETAP2METAP1DAO
SCHEMBL17163825 0.73 AOC3 (0.44) AOC3PDGFRBFGFR1KDRGSK3B
SCHEMBL10653932 0.72 GSK3B (0.53) AOC3PDGFRBFGFR1KDRGSK3B
SCHEMBL14764843 0.70 GSK3B (0.51) KDRGSK3BESR1RAB9ANPC1
SCHEMBL6016016 0.69 GSK3B (0.58) AOC3KDRGSK3BESR1RAB9A
SCHEMBL31537211 0.69 GSK3B (0.58) AOC3KDRGSK3BESR1RAB9A
SCHEMBL19100764 0.68 GSK3B (0.60) KDRGSK3BESR1RAB9ANPC1
SCHEMBL31595618 0.68 ADORA3 (0.61) PDGFRBFGFR1KDRRAB9ANPC1
SCHEMBL12894435 0.68 ADORA3 (0.61) PDGFRBFGFR1KDRRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0541153-A1 1,3-Dihydro-2H-imidazo[4,5-b]-quinolin-2-one derivatives as phosphodiesterase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 1993-05-12 EP claimed
US-5153104-A Negative-acting photothermographic imaging systems comprising also a nitrate, an initiator, a leuco dye and a binder; colorfastness; clean background MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-10-06 US claimed
US-20100317650-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS NYCOMED GMBH (DE) 2010-12-16 US disclosed
US-7790710-B2 Imidazopyridine derivatives useful as iNOS inhibitors NYCOMED GMBH (DE) 2010-09-07 US disclosed
EP-1866306-B1 IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS NYCOMED GMBH (DE) 2009-06-17 EP disclosed
US-20090131399-A1 Imidazopyridine Derivatives Useful as iNOS Inhibitors NYCOMED GMBH (DE) 2009-05-21 US disclosed
US-7390819-B2 Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors ALTANA PHARMA AG (DE) 2008-06-24 US disclosed
WO-2008031788-A1 AMINOAZEPINE DERIVATIVES AS HIGHLY EFFICIENT INHIBITORS OF THE INDUCIBLE NITRIC OXIDE SYNTHASE NYCOMED GMBH (DE) 2008-03-20 WO disclosed
EP-1866306-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS Nycomed GmbH (DE) 2007-12-19 EP disclosed
WO-2006103255-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS NYCOMED GMBH (DE) 2006-10-05 WO disclosed
EP-1599473-B1 IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS ALTANA PHARMA AG (DE) 2006-09-20 EP disclosed
US-20060160839-A1 Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors ALTANA PHARMA AG (DE) 2006-07-20 US disclosed
EP-1599473-A1 IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS ALTANA Pharma AG (DE) 2005-11-30 EP disclosed
WO-2004076451-A1 IMIDAZO[4,5-B]QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS ALTANA PHARMA AG (DE) 2004-09-10 WO disclosed
EP-0541153-A1 1,3-Dihydro-2H-imidazo[4,5-b]-quinolin-2-one derivatives as phosphodiesterase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 1993-05-12 EP disclosed
EP-0541153-A1 1,3-Dihydro-2H-imidazo[4,5-b]-quinolin-2-one derivatives as phosphodiesterase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 1993-05-12 EP disclosed
US-4965179-A Silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1990-10-23 US disclosed
EP-0086230-B1 MEROCYANINE-CYANINE-MEROCYANINE (MCM) ELECTRICALLY PHOTOSENSITIVE COLORANTS EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1987-01-07 EP disclosed
US-4463076-A Merocyanine-cyanine-merocyanine (MCM) electrically photosensitive colorants for photoelectrophoretic imaging EASTMAN KODAK COMPANY (US) 1984-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160839-A1 Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors NOS2, NOS1, NOS3 AOC3 386/4885PDGFRB 2488/4885FGFR1 3760/4885
US-20100317650-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS NOS2, NOS1, ARG1 AOC3 472/4885PDGFRB 2095/4885FGFR1 2922/4885
US-20090131399-A1 Imidazopyridine Derivatives Useful as iNOS Inhibitors NOS2, NOS1, ARG1 AOC3 472/4885PDGFRB 2095/4885FGFR1 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.